Studieoverzicht
BOOG nr.: |
Status: ( Follow up )
|
Indication: ( View all )
|
Subindication: |
Menopausal status: |
2018-01 TRAIN-3 | Follow up | Neoadjuvant | HER2+, any HR | Not applicable | ||||||||||||||
2017-05 SELECT | Follow up | Locoregional | Not applicable | Both pre- and postmenopausal | ||||||||||||||
2017-04 BYLieve | Follow up | Advanced/metastatic | HER2- HR+ | Not applicable | ||||||||||||||
2017-01 NEOLBC | Follow up | Neoadjuvant | HER2- HR+ | Postmenopausal | ||||||||||||||
2016-03 PRECISE | Follow up | Adjuvant | Not applicable | Not applicable | ||||||||||||||
2016-02 PALLAS | Follow up | Adjuvant | HER2- HR+ | Both pre- and postmenopausal | ||||||||||||||
2016-01 TOP-1 | Follow up | Data registration | HER2- HR+ | Postmenopausal | ||||||||||||||
2015-03 POSITIVE | Follow up | Adjuvant | Any HER2, HR+ | Premenopausal | ||||||||||||||
2015-02 MonaLEEsa-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2015-01 Monarch-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2014-03 OLYMPIA | Follow up | Adjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2014-02 BRAVO | Follow up | Advanced/metastatic | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2013-08 lumpectomie | Follow up | Locoregional | Not applicable | Not applicable | ||||||||||||||
2013-05 BELLE-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-04 DIRECT | Follow up | Neoadjuvant | HER2-, any HR | Both pre- and postmenopausal | ||||||||||||||
2013-02 Male BC prospectief | Follow up | Data registration | Not applicable | Not applicable | ||||||||||||||
2012-03 TRAIN-2 | Follow up | Neoadjuvant | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2012-02 SafeHer | Follow up | Adjuvant | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2011-02 APHINITY | Follow up | Adjuvant | HER2+, any HR | Both pre- and postmenopausal | ||||||||||||||
2011-01 Abiraterone | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2010-04 D-Care | Follow up | Adjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2009-03 DCIS | Follow up | Locoregional | Not applicable | Not applicable | ||||||||||||||
2009-01 IRMA | Follow up | Locoregional | Not applicable | Not applicable | ||||||||||||||
2006-05 IDEAL | Follow up | Adjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2006-04b TEAM IIb | Follow up | Adjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2006-03 SUPREMO | Follow up | Locoregional | Not applicable | Not applicable | ||||||||||||||
2005-03 MINDACT | Follow up | Adjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2005-02 MATADOR | Follow up | Adjuvant | Any HER2, any HR | Both pre- and postmenopausal | ||||||||||||||
2004-01 Young Boost | Follow up | Locoregional | Not applicable | Not applicable | ||||||||||||||
2003-04 Pregnancy | Follow up | Not applicable | Any HER2, any HR | Premenopausal |